Whilst its frustrating to see us languishing here and share your frustrations on news and DT, I will actually be topping up again come next week. These moments are in my view, precisely when you do top up, if you have confidence in the business and it becomes a forgotten share. I thank the market for lowering my average.
yes over months this would add up, but surely TR1's would need to be taken into account over this time frame. We've seen 2 this year from DT and they're not significant to his holding. We've seen none from CPI since last year. I appreciate nfx took the foot off the gas with governance/due diligence on reporting in appropriate time frames, but since the board changes I have assumed this would not be repeated. I still think the majority are traders exiting a position taken short term in the hope of a Q1 deal.
worth noting that a similar rise in mcap for NFX would take us to between 18-19p. I do think however there is potential for NFX to become a unicorn in future, if the company plays its card rights and we have no more repeats of the fiasco's of late.
no disrespect Barwickman; but coming from the king of pointless posters, that's pretty rich. Who made you the msg board police? Everyone here is entitled to their own views, including you. All you seem to be doing the last few days is slating others for expressing theirs.
I don't believe K Keegan is a replacement to Dave T at all, I believe that Karl has been drafted in at the recommendation of C Blackwell, as the 2 have worked together in the past at Vectura. Karl looks like he has extensive experience in the corporate development space for Biotech, which i think is desperately needed at this moment. Both from the stage nfx are at and the recent issues we've faced. I do hope C Blackwell becomes the permanent chairman too.
Thanks for the reply Aim, and fair point Soup, truth is I don't know how much he was involved with or the reason for his dismissal.
I just want to know what has gone on in the last month, as it has left an uneasiness that previously wasn't there, this co. represent a huge share of my portfolio which is unusual for me and goes against my rules/better judgement .
I was never investing in NFX for NXP001 that just proved the tech works, was never interested in the Chinese payment, as its relatively immaterial and i do not trust the Chinese generally with business. I hope when all is said and done that the BOD have learned lessons from this and choose to focus on other markets with greater vigour. My full faith is with Dan and Joanne, whilst CEO is Green, he's talented, passionate and appears unusually honest, very Glad Chris Blackwell is there to support him. Role on with the news i am interested in NXP002 and NXP004 with a side of Ebers.
Hope big business doesn't cloud their optimism or screw them over as is so often the case with other talented individuals in the medical sector.
Haven't sold a share and continue to accumulate looking forward to brighter skies.
Aim, We have all assumed that DT's dismissal is from lack of progress on China deal given this was his main project, also the very strange sell of a very small proportion of his shares, owing to further embarrassment for the company from someone that should have known better, I also believe this is why he was voted off i should add. But do you think there is a risk, given how close he was to china that data was shared prior to payment being received?
For those wondering around what NFX play is with Ebers, you only have to look at the Opioid crisis, which you can quickly google to understand. Far too many pain treatments are based on Opioid derivatives, (i.e. oxycodone, morphine, codeine, fentanyl etc.). Opioid's are addictive and far from ideal for long term use, they have many negative side effects. Cannabis has pain relief and nausea relief properties and have been under explored and in the past unreliable as pharma therapies, as most are natural molecules presenting companies with issues for patents and isolation of unwanted properties. What is known is that it is far less physically addictive. Cannabis has a family of molecules (cannabinoids) of which the most known/ most largely concentrated in plants due to imbreading for their desired effects are THC and CBD. There are many cannabinoids in the family not just these 2 many have never been tested/concentrated for purposes of pharmaceutical therapies. Its a huge opportunity that warrants research and whilst i am more focused on NXP002 and NXP004 for value incursion events with this company, i completely understand Dan's interest in this area commercially. To compare their approach to that of the influx of CBD products (i would agree snake oil therapies is a good comparison) or other cannabis mainia companies we've seen mainly from Canada/US are not seeing the bigger picture with NFX's plans in this area. Its kinda like comparing the company that was planning to develop codeine with someone offering poppy seeds to rub on your skin.